{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:40:15Z","timestamp":1792694415339,"version":"4.5.0"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:00:00Z","timestamp":1730073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Abraxane plays a crucial role in the treatment of various types of cancer, despite the considerable attention it has garnered for its adverse drug events (ADEs). Nevertheless, there is currently a significant lack of comprehensive real-world pharmacovigilance studies on the ADEs associated with Abraxane.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of ADEs associated with Abraxane using data mining from the FAERS database, analyzing data from 2005 to 2023. In a real-world setting, we quantified and visualized the signals of these ADEs using four pharmacovigilance algorithms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The FAERS database identified a total of 10,230 adverse event reports associated with Abraxane. The study revealed that Abraxane-related adverse drug events involved 27 system organ classes (SOC), with the strongest signals associated with the lymphatic and hematological systems and hepatobiliary disorders. Additionally, we identified 70 significant Preferred Terms (PT) signals, which included some critical adverse events not highlighted in the product labeling, such as cystoid macular edema. Further analysis of the timing of adverse reactions showed a median onset time of 41\u00a0days. Most adverse events (AEs) occurred within the first month of using Abraxane (43.5%), although some were still possible 1\u00a0year after treatment (3.5%). Gender-specific analysis indicated that high-risk AEs differed between females (nausea, vomiting, and erythema) and males (febrile neutropenia, disseminated intravascular coagulation, and upper gastrointestinal bleeding).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The examined results provide crucial recommendations for optimizing the administration of Abraxane, enhancing its effectiveness, and mitigating potential adverse effects. This knowledge will substantially facilitate the implementation of the substance in clinical settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1448144","type":"journal-article","created":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:46:46Z","timestamp":1730076406000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Adverse event profile of albumin-bound paclitaxel: a real-world pharmacovigilance analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Yuanqiong","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shentao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rutie","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,10,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS)","volume":"1","author":"Anand","year":"2019","journal-title":"JACC. CardioOncology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1007\/s13311-021-01142-2","article-title":"Chemotherapy-induced peripheral neuropathy: mechanisms and therapeutic avenues","volume":"18","author":"Bae","year":"2021","journal-title":"Neurother"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1007\/s10620-017-4633-8","article-title":"From harmful treatment to secondary gain: adverse event reporting in dyspepsia and gastroparesis","volume":"62","author":"Bielefeldt","year":"2017","journal-title":"Dig. Dis. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1097\/j.pain.0000000000001831","article-title":"Targeting interleukin-20 alleviates paclitaxel-induced peripheral neuropathy","volume":"161","author":"Chen","year":"2020","journal-title":"Pain"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/s0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet (London, England)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","article-title":"Model of chemotherapy-induced myelosuppression with parameter consistency across drugs","volume":"20","author":"Friberg","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ijc.34332","article-title":"Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: a pharmacovigilance analysis","volume":"152","author":"Gu","year":"2023","journal-title":"Int. J. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1515\/sjpain-2018-0050","article-title":"Colored body images reveal the perceived intensity and distribution of pain in women with breast cancer treated with adjuvant taxanes: a prospective multi-method study of pain experiences","volume":"18","author":"Hellerstedt-B\u00f6rjesson","year":"2018","journal-title":"Scand. J. pain"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.3892\/ol.2017.5998","article-title":"Efficacy and tolerability of nanoparticle albumin-bound paclitaxel in combination with carboplatin as a late-phase chemotherapy for recurrent and advanced non-small-cell lung cancer: a multi-center study of the Fukushima lung cancer association group of surgeons","volume":"13","author":"Higuchi","year":"2017","journal-title":"Oncol. Lett."},{"key":"B11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.biopha.2018.12.110","article-title":"The combination of gemcitabine and nab-paclitaxel as a novel effective treatment strategy for undifferentiated soft-tissue sarcoma in a patient-derived orthotopic xenograft (PDOX) nude-mouse model","volume":"111","author":"Higuchi","year":"2019","journal-title":"Biomed. & Pharmacother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2174\/1570159X15666170915143217","article-title":"Prevention and treatment for chemotherapy-induced peripheral neuropathy: therapies based on CIPN mechanisms","volume":"17","author":"Hu","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"B13","first-page":"1038","article-title":"Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel","volume":"8","author":"Ibrahim","year":"2002","journal-title":"Clin. cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"x313","DOI":"10.1093\/annonc\/mds314","article-title":"Prevention and handling of acute allergic and infusion reactions in oncology","volume":"23","author":"Joerger","year":"2012","journal-title":"Ann. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.biopha.2007.08.008","article-title":"Paclitaxel albumin-bound particles (abraxane) in combination with bevacizumab with or without gemcitabine: early experience at the University of Miami\/Braman Family Breast Cancer Institute","volume":"61","author":"Lobo","year":"2007","journal-title":"Biomed. & Pharmacother."},{"key":"B16","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1200\/JCO.2005.10.517","article-title":"Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28","volume":"23","author":"Mamounas","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"100742","DOI":"10.1016\/j.drup.2020.100742","article-title":"Taxanes in cancer treatment: activity, chemoresistance and its overcoming","volume":"54","author":"Mosca","year":"2021","journal-title":"Drug Resist. Updat."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2217\/pgs.15.68","article-title":"Predicting paclitaxel-induced neutropenia using the DMET platform","volume":"16","author":"Nieuweboer","year":"2015","journal-title":"Pharmacogenomics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Briefings Bioinforma."},{"key":"B20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40264-024-01404-w","article-title":"Detection algorithms for simple two-group comparisons using spontaneous reporting systems","volume":"47","author":"Noguchi","year":"2024","journal-title":"Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"7785","DOI":"10.1200\/JCO.2004.00.6148","article-title":"Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies","volume":"23","author":"Nyman","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1073\/pnas.77.3.1561","article-title":"Taxol stabilizes microtubules in mouse fibroblast cells","volume":"77","author":"Schiff","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"18","author":"Shepherd","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"e2006050118","DOI":"10.1073\/pnas.2006050118","article-title":"Integrins protect sensory neurons in models of paclitaxel-induced peripheral sensory neuropathy","volume":"118","author":"Shin","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B25","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1684\/ejd.2016.2833","article-title":"Dermatological adverse events with taxane chemotherapy","volume":"26","author":"Sibaud","year":"2016","journal-title":"Eur. J. dermatology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1634\/theoncologist.2011-S1-30","article-title":"Chemotherapy: updates and new perspectives","volume":"16","author":"Swain","year":"2011","journal-title":"Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1080\/21691401.2018.1552595","article-title":"Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis","volume":"47","author":"Tan","year":"2019","journal-title":"Artif. cells, nanomedicine, Biotechnol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.4103\/ijp.ijp_640_22","article-title":"Safety signals of albumin-bound paclitaxel: data mining of the Food and Drug Administration adverse event reporting system","volume":"55","author":"Wang","year":"2023","journal-title":"Indian J. Pharmacol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1159\/000533999","article-title":"Cystoid macular edema following treatment with nanoparticle albumin-bound paclitaxel and atezolizumab for metastatic breast cancer","volume":"16","author":"Yamane","year":"2023","journal-title":"Case Rep. Oncol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/17425255.2023.2219390","article-title":"A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database","volume":"19","author":"Yang","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","article-title":"nab-Paclitaxel mechanisms of action and delivery","volume":"170","author":"Yardley","year":"2013","journal-title":"J. Control. release"},{"key":"B32","doi-asserted-by":"publisher","first-page":"773540","DOI":"10.3389\/fonc.2021.773540","article-title":"Intravitreal ranibizumab had limited effect on cystoid macular edema due to albumin-bound paclitaxel: a case report and literature review","volume":"11","author":"Ye","year":"2021","journal-title":"Front. Oncol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1016\/j.jtho.2021.03.027","article-title":"Phase 3 trial comparing nanoparticle albumin-bound paclitaxel with docetaxel for previously treated advanced NSCLC","volume":"16","author":"Yoneshima","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. allergy Clin. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1182113","DOI":"10.3389\/fphar.2023.1182113","article-title":"Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database","volume":"14","author":"Zhao","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"101967","DOI":"10.1016\/j.eclinm.2023.101967","article-title":"Psychiatric disorders associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"59","author":"Zhou","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B37","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.cell.2019.05.035","article-title":"The cytoplasmic DNA sensor cGAS promotes mitotic cell death","volume":"178","author":"Zierhut","year":"2019","journal-title":"Cell"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1448144\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,28]],"date-time":"2024-10-28T00:46:48Z","timestamp":1730076408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1448144\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,28]]},"references-count":37,"alternative-id":["10.3389\/fphar.2024.1448144"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1448144","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,28]]},"article-number":"1448144"}}